In a Phase 3 , randomized , double-blind , double-dummy study ( NCT01644474 ) , patients ( low-density lipoprotein cholesterol [ LDL-C ] 100-190 mg/dL , 10-year risk of fatal cardiovascular events 1 % - < 5 % [ systemic coronary risk estimation ] ) were randomized to ezetimibe 10mg/day ( n = 51 ) or alirocumab 75 mg subcutaneously ( via 1-mL autoinjector ) every 2 weeks ( Q2W ) ( n = 52 ) , with dose up-titrated to 150 mg Q2W ( also 1 mL ) at week 12 if week 8 LDL-C was 70 mg/dL .